These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26845928)

  • 21. [Treatment choice of the antiviral agent for the hepatitis C].
    Karino Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():269-73. PubMed ID: 26845943
    [No Abstract]   [Full Text] [Related]  

  • 22. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man.
    Franco S; Tural C; Nevot M; Moltó J; Rockstroh JK; Clotet B; Martinez MA
    Gastroenterology; 2014 Sep; 147(3):599-601.e1. PubMed ID: 24859204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Excitement grows for potential revolution in hepatitis C virus treatment.
    Opar A
    Nat Rev Drug Discov; 2010 Jul; 9(7):501-3. PubMed ID: 20592732
    [No Abstract]   [Full Text] [Related]  

  • 26. [Progress in Examination and Treatment of Hepatitis C Virus].
    Suda G; Sakamoto N
    Rinsho Byori; 2015 Jun; 63(6):762-7. PubMed ID: 26548242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New therapeutic prospects in HCV treatment.
    Almasio PL; Ingrassia D; Vergara B; Filosto S
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):775-9. PubMed ID: 19053890
    [No Abstract]   [Full Text] [Related]  

  • 28. Practical consequences of hepatitis C virus quasispecies for target-specific antivirals.
    Fanning LJ
    J Infect Dis; 2008 Sep; 198(6):797-9. PubMed ID: 18637751
    [No Abstract]   [Full Text] [Related]  

  • 29. Changing the face of hepatitis C management - the design and development of sofosbuvir.
    Noell BC; Besur SV; deLemos AS
    Drug Des Devel Ther; 2015; 9():2367-74. PubMed ID: 25987834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
    Butt AA; Kanwal F
    Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon-free strategies without a nucleoside/nucleotide analogue.
    Welzel TM; Zeuzem S
    Semin Liver Dis; 2014 Feb; 34(1):47-57. PubMed ID: 24782258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
    Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
    Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
    Wyles DL
    J Infect Dis; 2013 Mar; 207 Suppl 1():S33-9. PubMed ID: 23390303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection.
    Gentile I; Buonomo AR; Zappulo E; Coppola N; Borgia G
    Expert Rev Anti Infect Ther; 2014 Oct; 12(10):1179-86. PubMed ID: 25096404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals.
    Rockstroh JK
    Liver Int; 2015 Jan; 35 Suppl 1():51-5. PubMed ID: 25529087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis: HCV virologic response--new nomenclature recommendations.
    Pol S
    Nat Rev Gastroenterol Hepatol; 2012 Nov; 9(11):619-20. PubMed ID: 22926152
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment for hepatitis C before and after liver transplantation].
    Ueda Y; Marusawa H
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():306-10. PubMed ID: 26845950
    [No Abstract]   [Full Text] [Related]  

  • 38. Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.
    Harrington PR; Deming DJ; Komatsu TE; Naeger LK
    Clin Infect Dis; 2015 Aug; 61(4):666-7. PubMed ID: 26002846
    [No Abstract]   [Full Text] [Related]  

  • 39. [Expert advices for evaluating clinical trials of direct-acting antiviral agents for hepatitis C].
    Research Group for New Drug's Clinical Evalutaion of Critical Diseases and Platform Construction of Integrated Technology
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):161-4. PubMed ID: 27095756
    [No Abstract]   [Full Text] [Related]  

  • 40. Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.
    Kwong AD; Najera I; Bechtel J; Bowden S; Fitzgibbon J; Harrington P; Kempf D; Kieffer TL; Koletzki D; Kukolj G; Lim S; Pilot-Matias T; Lin K; Mani N; Mo H; O'Rear J; Otto M; Parkin N; Pawlotsky JM; Petropoulos C; Picchio G; Ralston R; Reeves JD; Schooley RT; Seiwert S; Standring D; Stuyver L; Sullivan J; Miller V; ; ; ;
    Gastroenterology; 2011 Mar; 140(3):755-60. PubMed ID: 21255574
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.